

Figure S1 A. Representative immunohistochemistry micrographs of SphK1 expression from primary ccRCC tissue and the corresponding lung metastasis (left 200 \times magnification, right 400 \times magnification). B. LC-MSMS analysis for sphingosine levels in plasma from a small group of ccRCC patients (N=30) and normal individuals (N=20). C.

Quantitative RT-PCR assay for SphK1 mRNA level in a panel of ccRCC-derived cell lines. SphK1 mRNA was higher in the ccRCC cell lines, including Caki-1, ACHN, A498, 786-O, and 769-P than in the immortalized human renal tubular epithelial cells line HK-2 which is not tumorigenic. ** P < 0.01. D. Western blot analysis of SphK1 protein in a panel of ccRCC-derived cell lines and HK-2 cell line. E. Quantitative RT-PCR assay for SphK1 mRNA level in 786-O and Caki-1 cells stably transfected with shRNAs. ** P < 0.01. F. Western blot analysis of SphK1 protein in 786-O and Caki-1 cells stably transfected with shRNAs.




Figure S2 A. Cell viability was measured by MTT assay at 0, 24, 48, 72 and 96 hours in Caki-1 cells stably transfected with SphK1 short hairpin RNAs (sh#1 and #2) or control shRNA (sh-neg). The data are presented as the means \pm S.D. from three independent experiments. B. The bar chart represents the percentage of EdU incorporation assay of 786-O and Caki-1 cells stably expressing SphK1 shRNAs (sh#1 and #2) or control shRNA. ** *P* < 0.01. C. The percentage of apoptotic 786-O and Caki-1 cells stably expressing SphK1 shRNAs (sh#1 and #2) or control shRNA was determined by flow cytometric analysis. The data represent the means \pm SD from three independent experiments. **P* < 0.05, ** *P* < 0.01. D. The bar chart represents the percentage of Caki-1 cells stably expressing SphK1 shRNAs (sh#1 and #2) or control shRNA is stably expressing SphK1 shRNAs (sh#1 and #2) or control shRNA was determined by flow cytometric analysis. The data represent the means \pm SD from three independent experiments. **P* < 0.05, ** *P* < 0.01. D. The bar chart represents the percentage of Caki-1 cells stably expressing SphK1 shRNAs (sh#1 and #2) or control shRNA in the G0/G1, S, or G2/M phase, as indicated. The data are presented as the means \pm SD from three independent experiments. **P* < 0.05.




Figure S3 A. Representative images of migration and invasion assays in Caki-1 cells stably expressing SphK1 shRNAs (sh#1 and #2) or control shRNA (left) and quantification of the relative migration and invasion cell number (right). Scale bar = 100 μ m. * *P* < 0.05, ** *P* < 0.01. B. Representative immunohistochemistry micrographs of Ki67 expression from SphK1-shRNA xenograft tumors (left) and quantification of the relative Ki67 positive cell number (right).




Figure S4 A. Western blot analysis of SphK1 protein in 786-O and Caki-1 cells with overexpression of SphK1 or control vector. B. Cell viability was measured by MTT assay at 0, 24, 48 and 72 hours in Caki-1 cells with overexpression of SphK1 or control vector. The data are presented as the means \pm S.D. from three independent experiments. C. Quantification of the relative migration and invasion of 786-O and Caki-1 cells with overexpression of SphK1 or control vector. ** *P* < 0.01.